Leadership in RNAi
These are exciting times for RNAi therapeutics; important scientific and clinical advancements are being made at a very rapid pace. The discovery of RNAi has been widely acknowledged as a major breakthrough in biology, and the belief that this technology has the potential to make a broad and significant impact in medicine is stronger than ever. Alnylam is leading the effort in translating the science of RNAi into a robust drug discovery capability, with the goal of building a sustainable product pipeline of innovative medicines.
At Alnylam, we are unwavering in our commitment to scientific excellence, and we are driven by our dedication to the highest of scientific standards. A testament to this underlying tenet at Alnylam is the publication of our research in world-leading, peer-reviewed scientific journals, such as Nature, Nature Medicine, Nature Biotechnology, and Cell. We believe our numerous publications and collaborations with some of the world's best research labs are important measures of our position as scientific leaders in the RNAi field. Our scientific papers also serve to demonstrate to leading academic scientists, clinicians, and pharmaceutical executives the potential impact of our discoveries and the opportunity for RNAi therapeutics to become a new therapeutic approach in medicine, in addition to Alnylam's commitment to and leadership in translating and advancing the field.
RNAi 2010 Plan
To set the stage for the future, we launched our "RNAi 2010" initiative focused on achieving major scientific, clinical and business milestones by the end of 2010. We believe that execution on our "RNAi 2010" plan will continue to advance RNAi therapeutics as a transformative approach for new medicines and further our mission of building a leading biopharmaceutical company founded on RNAi.
Scientific Leadership. By the end of 2010, we expect to broaden our leadership and significantly expand the scope of delivery solutions for RNAi therapeutics. This will be achieved by the continued scientific leadership of Alnylam scientists and current academic and industry collaborators and through a significant external effort to form new delivery technology partnerships. This effort will include the expansion of the range of tissues and cell types where the company aims to achieve efficient delivery of RNAi therapeutics with both direct and systemic delivery approaches.
Clinical Pipeline. By the end of 2010, we expect to have four or more RNAi therapeutic programs in clinical development. These will include direct and systemic RNAi programs, Alnylam proprietary and 50/50 partnership programs, and siRNA and miRNA therapeutics.
New Business Collaborations. Based on our scientific, clinical, and IP leadership, we expect to form four or more new major business collaborations by the end of 2010. These are expected to include the completion of additional broad platform alliances, similar to Roche, but also alliances focused on specific RNAi therapeutic programs.
